BRIEF-Kalytera Therapeutics Says Results Of Phase 2 Clinical Study In Prevention Of Graft Versus Host Disease Are Expected By Q3 2018
December 07, 2017 at 08:42 AM EST
* KALYTERA ANNOUNCES INITIATION OF PHASE 2 CLINICAL STUDY IN PREVENTION OF GRAFT VERSUS HOST DISEASE AND AGREEMENT WITH THE SALZMAN GROUP OF ISRAEL TO MANAGE AND PARTIALLY FUND THE STUDY TO BE LED BY A WORLD CLASS TEAM
